Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for primary care physicians, gastroenterologists, pediatricians, family medicine, nurses, physician assistants, and other clinicians who treat and manage children with eosinophilic esophagitis.
The goal of this activity is for learners to be better able to distinguish differences in presentation and outcome among Black and White children with eosinophilic esophagitis.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 9/9/2023. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 9/9/2022
Valid for credit through: 9/9/2023
processing....
Eosinophilic esophagitis (EoE) is characterized by the infiltration of eosinophils into the esophageal mucosa, and it is increasing in prevalence. The authors of the current study provide a brief review of EoE as part of their research.
EoE is associated with a range of upper gastrointestinal symptoms, including dysphagia, vomiting, regurgitation, and feeding difficulties. As expected with an eosinophilic disease, three quarters of children with EoE have other atopic illness.
EoE appears to predominantly affect boys more than girls, with a ratio of approximately 3:1. EoE has also been thought to affect White children in 85% to 90% of cases. However, more recent evidence suggests that EoE may be more common among Black individuals than previously thought. The current study addresses the question of whether there are differences in the clinical journey of EoE based on race.
Black children with EoE are more likely to present with atopic comorbidities and failure to thrive and are less likely to adhere to therapy than non-Black children, suggests the largest study to date to compare the 2 groups.
According to the researchers, Black children were more likely to have food allergies, atopic dermatitis, asthma, and allergic rhinitis. In addition, failure to thrive at presentation was more than twice as common among Black patients, whereas non-Black patients were around 3 times as likely to present with abdominal pain.
Although there were no significant differences in the rates of remission on medical therapy between the 2 groups, Black patients were substantially more likely to be nonadherent to regimens than their non-Black counterparts.
"Overall, there were some important differences between our two cohorts suggesting Black patients may present with more severe symptoms or have issues with access to care," said lead researcher Sofia Edwards-Salmon, MD, from Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, and colleagues.
The findings were published online in the Journal of Pediatric Gastroenterology and Nutrition.
An Increasingly Common ConditionAccording the authors, EoE is an increasingly common chronic, immune-related condition characterized by eosinophilic infiltration of the esophagus, causing regurgitation, dysphasia, feeding difficulties, and vomiting. Atopic comorbidities accompany the disease in around 75% of patients.
Although the pathogenesis of EoE is not fully understood, males are predominately affected (male-to-female ratio of 3:1), and 85% to 90% of cases occur in White people.
The authors note that recent smaller studies have suggested that Black children are affected by EoE to a greater degree than previously thought, raising questions over the clinical care of Black individuals.
To investigate further, they conducted a retrospective chart review of patients aged from 1 to 17 years who were diagnosed with EoE. The researchers identified eligible Black patients and then identified a sample of non-Black patients who were matched by age and sex. In all, 143 Black children and 142 non-Black children were included. The median age at diagnosis was 5.1 years and 6.7 years, respectively. More than twice as many Black children than non-Black children had public health insurance (66.2% vs 30.7%).
The authors found that non-Black children were significantly more likely to present with abdominal pain (33.1% vs 11.2%), whereas Black children were more likely to present with failure to thrive/poor growth (32.2% vs 12.7%).
In regard to endoscopic findings, Black children were more likely to have strictures (3.5% vs 0.0%), but no other significant differences were found. The 2 groups underwent a similar number of esophagogastroduodenoscopies during follow-up (mean number of procedures, 4 among Black patients vs 3 among non-Black patients).
In addition, atopic comorbidities were more common among Black children than non-Black children: food allergies (52.4% vs 35.9%), atopic dermatitis (50.3% vs 27.5%), asthma (47.7% vs 28.9%), and allergic rhinitis (40.6% vs 23.9%). A family history of atopy was recorded for 65% of Black patients vs 47.2% of non-Black patients.
Notably, the authors found no overall significant differences in the therapies used for Black and non-Black patients. There also was no significant difference in the proportion of patients who achieved remission at some point (58.7% of Black patients vs 66.2% of non-Black patients). However, nonadherence to medical therapy was significantly more prevalent among Black patients (33.6% vs 10.9%).
Similar proportions were lost to follow-up (46.9% of Black patients vs 43.6% of non-Black patients).
Raising AwarenessDr Edwards-Salmon told Medscape Medical News that although there are many potential reasons for the differences, the most likely would be access to care and/or socioeconomic differences.
She explained that their biggest hope in publishing the results of their study is to increase physician awareness of EoE in the Black pediatric population and how its presentation may differ. The aim is to achieve earlier treatment and earlier remission, and therefore better outcomes, she said.
Dr Edwards-Salmon suggested that adherence could be improved by including patient surveys on medication access and affordability, as well as having information regarding a parent or guardian's daily schedule, which would enable providers to come up with a plan on how to most easily supervise medication.
Reached for comment, Vincent A. Mukkada, MD, associate professor, University of Cincinnati Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, said it was "interesting that they are not seeing major differences in treatment response between the Black population compared to their other patients."
He told Medscape Medical News that, in contrast, "we and other groups have seen that some of these patients, particularly the very young ones with multiple atopic diseases, have been very challenging to treat effectively."
Dr Mukkada, who was not involved in the study, said that although he agrees that socioeconomics and access to care play major roles in the differences seen, he would hesitate to jump to the conclusion that these are the sole or dominant forces.
"In fact, the increased prevalence of other atopic diseases and failure to thrive in the Black cohort might just as well be due to a biologic difference in atopic predisposition, or perhaps the greater proportion of patients with failure to thrive might be secondary to their increased atopic burden," he said.
Dr Mukkada added that it would have been interesting to have seen other objective markers, such as blood counts, to see whether peripheral eosinophilia, for instance, was increased among the Black patients. In addition, it would be interesting to look at gene expression profiles.
The study was funded by the Children's Healthcare of Atlanta Butcher Resident Research Award and Emory School of Medicine Research Training in Translational GI and Liver. Dr Edwards-Salmon and Dr Mukkada have disclosed no relevant financial relationships.
J Pediatr Gastroenterol Nutr. Published online July 6, 2022.[1]